FDA Floats Eliminating Multi-Ingredient Pediatric Cold Products
This article was originally published in The Tan Sheet
Executive Summary
FDA suggests the drug industry consider making pediatric cough/cold formulations available only as single-ingredient products, according to an agency report
You may also be interested in...
FDA Urged To Change OTC Monograph System, But Not In Midstream
“Moving away from the monograph system when we are so close to the end” would “risk setting back the OTC drug review many years or even decades,” CHPA head Scott Melville says at an FDA public hearing. Other stakeholder s explain how the monograph system has failed industry and consumers.
FDA Urged To Change OTC Monograph System, But Not In Midstream
“Moving away from the monograph system when we are so close to the end” would “risk setting back the OTC drug review many years or even decades,” CHPA head Scott Melville says at an FDA public hearing. Other stakeholder s explain how the monograph system has failed industry and consumers.
J&J Ready To Capitalize On Zyrtec OTC Launch As Allergy Drug Hits Shelves
Johnson & Johnson's consumer product business is positioned to capitalize on the launch of nonprescription Zyrtec (cetirizine HCl) allergy medicine, J&J CEO Bill Weldon said during the firm's year-end analyst meeting Jan. 22